Natural Language Processing for Life Sciences

The pharmaceutical and life sciences industry runs on language — millions of scientific papers, clinical trial protocols, regulatory submissions, adverse event reports, patient records, and drug labels. For decades, extracting actionable intelligence from this ocean of text required armies of skilled humans. Natural Language Processing has fundamentally changed that equation. From accelerating drug discovery to automating pharmacovigilance, NLP is now one of the most consequential technologies in biopharma.

Drug Discovery and Literature Mining

The biomedical literature doubles roughly every nine years. No research team can read it all. NLP systems trained on PubMed, patent databases, clinical trial registries, and proprietary research corpora can surface non-obvious connections between genes, proteins, diseases, and candidate compounds — connections that might take human scientists years to notice, if ever. BenevolentAI has built knowledge graphs from over 50 million biomedical documents, using relationship extraction models to identify novel drug-target hypotheses. Their NLP-driven platform identified baricitinib as a potential COVID-19 treatment months before clinical evidence confirmed it. Recursion Pharmaceuticals combines high-content imaging with NLP-derived biological context to prioritize which compounds enter their experimental pipeline. IQVIA's Linguamatics platform provides pharmaceutical companies with configurable NLP workflows for mining competitive intelligence, biomarker research, and mechanism-of-action literature at scale.

Clinical Trials: Protocol Design and Patient Matching

Clinical trial failure rates remain stubbornly high — over 90% of drug candidates that enter Phase I never reach approval. A significant fraction of failures stem from poor patient selection and protocol design flaws that could have been caught earlier. NLP addresses both problems. Protocol intelligence tools from companies like Medidata (Dassault Systèmes) parse thousands of historical trial protocols to benchmark eligibility criteria, endpoint definitions, and dosing schedules against outcomes data, flagging design choices statistically associated with failure. On the recruitment side, NLP extracts structured patient phenotypes from free-text clinical notes in electronic health records — conditions, biomarkers, prior medications, contraindications — and matches them against trial eligibility criteria automatically. Tempus applies this approach in oncology, linking genomic profiles with NLP-derived clinical histories to identify trial candidates from real-world patient populations. Trials that leverage NLP-assisted recruitment have demonstrated enrollment acceleration of 30–50% in published studies.

Pharmacovigilance and Signal Detection

Regulators require pharmaceutical companies to monitor the safety of their products throughout their commercial lifecycle — a process called pharmacovigilance. The volume and variety of incoming safety data has exploded: formal adverse event reports, electronic health records, scientific literature, social media, patient forums, and call center transcripts all carry safety signals. NLP is now integral to processing this flood. Named entity recognition models identify drug names, medical concepts, and adverse event descriptions in unstructured text. Sentiment-aware classifiers distinguish patients expressing concern from those describing positive outcomes. Oracle's Argus Safety and Veeva Vault Safety both incorporate NLP layers for automated case triage and MedDRA coding — mapping free-text descriptions to standardized medical terminology. The FDA itself has invested heavily in NLP for its Sentinel surveillance network, which monitors post-market safety across linked insurance and EHR databases covering over 100 million patients.

Clinical Documentation and the EHR

The electronic health record is simultaneously the richest and most chaotic data source in medicine. Physician notes, discharge summaries, radiology reports, and operative records are written in the hybrid shorthand of clinical practice — full of abbreviations, negations, uncertainty hedges, and domain-specific jargon that confounds general-purpose language models. Specialized biomedical NLP systems have been trained to handle this complexity. Nuance's Dragon Medical One (now part of Microsoft) uses a combination of ASR and NLP to produce structured clinical documentation from physician dictation in real time, reducing documentation burden significantly. Amazon Comprehend Medical provides an API for extracting medical entities — conditions, medications, dosages, anatomical sites — from clinical text, used by health systems and biopharma partners building real-world evidence studies. Google's Med-PaLM 2 demonstrated performance approaching specialist-level accuracy on medical question answering benchmarks, pointing toward LLM-powered clinical decision support that can reason over a patient's longitudinal record.

Regulatory Affairs and Submission Intelligence

Regulatory submissions to the FDA, EMA, and other agencies are among the most complex documents in any industry — running to tens of thousands of pages for a single NDA or BLA. NLP tools are accelerating both the creation and review of these documents. On the sponsor side, companies including Veeva Systems and Certara have built NLP-assisted authoring environments that pull relevant data from study reports, flag labeling inconsistencies, and ensure cross-document coherence. On the agency side, the FDA's Center for Drug Evaluation and Research has deployed NLP tools to analyze incoming submissions more efficiently, cross-reference safety databases, and identify labeling claims that require additional scrutiny. Automated regulatory intelligence platforms — notably those from IQVIA and Citeline — continuously monitor global agency communications, guidance documents, and approval decisions, delivering synthesized alerts rather than requiring teams to manually track every jurisdiction.